A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Dispatch Biotherapeutics
Dispatch Biotherapeutics
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
Nammi Therapeutics Inc
Janssen Research & Development, LLC
Revolution Medicines, Inc.
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
NYU Langone Health
Arbele Limited
Replimune, Inc.
Pilatus Biosciences Inc
Beijing GoBroad Hospital
Boehringer Ingelheim
Second Affiliated Hospital, School of Medicine, Zhejiang University
Henry Ford Health System
University of Nebraska
Shanghai Juncell Therapeutics
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Elevation Oncology
Fox Chase Cancer Center
Revolution Medicines, Inc.
Indiana University
Revolution Medicines, Inc.
Inspirna, Inc.
Boehringer Ingelheim
Boehringer Ingelheim
University of Utah
Peking University
The Netherlands Cancer Institute
Celldex Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Five Prime Therapeutics, Inc.
University of Rochester
University of Chicago
Jiangsu HengRui Medicine Co., Ltd.
Revolution Medicines, Inc.
Silverback Therapeutics
Xencor, Inc.
Washington University School of Medicine
Curegenix Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Takeda
Themis Bioscience GmbH
Curegenix Inc.
Virginia Commonwealth University
IGF Oncology, LLC
Institut du Cancer de Montpellier - Val d'Aurelle